For several years, headlines have warned of an alarming rise in cancer among younger adults. Stories of high-profile diagnoses, coupled with expanding screening guidelines, have fueled a narrative that cancer is becoming an epidemic in people under 50.
A new study published in JAMA Internal Medicine challenges that assumption.
After examining three decades of national cancer data, researchers conclude that much of the apparent increase in early-onset cancer reflects intensified detection rather than a true surge in life-threatening disease.
Table of Contents
Incidence Is Rising. Mortality Is Not.
The study analyzed eight cancers with the fastest growing incidence rates in U.S. adults younger than 50: thyroid, anal, kidney, small intestine, colorectal, endometrial, pancreatic cancers, and multiple myeloma.
Since 1992, diagnoses of these cancers in younger adults have approximately doubled. Over the same period, combined mortality from these cancers has remained flat.
That contrast is critical. While incidence measures how often cancer is diagnosed, mortality reflects deaths from cancer and is far less influenced by how aggressively clinicians look for disease.
When diagnoses rise without a corresponding increase in deaths, it strongly suggests that more cancers are being found rather than more dangerous cancers occurring.
The Role of Diagnostic Scrutiny
Modern medicine detects abnormalities earlier and more often than ever before. Advances in imaging, blood testing, endoscopy, and pathology have expanded clinicians’ ability to identify very small or slow-growing tumors that may never cause symptoms.
This phenomenon is known as overdiagnosis. It occurs when a cancer is detected that would not have become clinically meaningful during a person’s lifetime.
Several cancers in the study show classic signs of this pattern.
- Thyroid cancer diagnoses have surged for decades while mortality has remained nearly unchanged, a well-documented example of overdiagnosis.
- Kidney cancer incidence has increased as abdominal imaging has become more common, often detecting small tumors found incidentally.
- Small intestine and pancreatic cancers show rising detection of indolent neuroendocrine tumors discovered during imaging or endoscopy for unrelated issues.
- Multiple myeloma is increasingly identified through routine blood tests, sometimes in patients without symptoms.
In each case, deaths have remained stable or declined, indicating that detection has outpaced disease severity.
Where the Increase Appears Real
Not all findings can be explained by overdiagnosis alone.
Two cancers showed modest but real increases in mortality among younger adults:
- Colorectal cancer, with mortality rising about 0.5 percent per year since the mid-2000s.
- Endometrial cancer, where incidence and mortality have risen together, likely influenced by rising obesity rates and changes in hysterectomy prevalence.
Even in these cases, the rise in diagnoses outpaces the rise in deaths, suggesting that both real disease increases and detection effects are at play.
Breast Cancer Tells a Different Story
Breast cancer remains the most common early-onset cancer, even though its relative incidence growth has been slower than other sites.
Despite more diagnoses in women under 50, breast cancer mortality in this group has fallen by roughly 50 percent over the past three decades. Most new cases are early-stage, with stable rates of advanced disease.
This pattern mirrors what was seen in older women after widespread adoption of mammography and reflects improvements in both screening intensity and systemic treatments rather than an explosion of aggressive disease.
Why This Distinction Matters
A cancer diagnosis carries consequences far beyond survival statistics.
For younger adults, unnecessary diagnoses can lead to:
- Exposure to surgery, chemotherapy, or radiation that may not improve outcomes
- Long-term complications such as infertility, organ damage, or secondary cancers
- Psychological distress, anxiety, and depression that can persist for years
- Financial strain from treatment, follow-up testing, and ongoing surveillance
Interpreting rising incidence as an epidemic without considering mortality risks accelerating these harms.
Rethinking Early Detection
The study’s authors caution against equating more testing with better outcomes. While early detection saves lives for certain cancers, expanding screening indiscriminately can also uncover disease that never needed treatment.
This concern is especially relevant as new technologies, including multi-cancer early detection blood tests, gain public attention despite limited evidence that they reduce mortality.
Effective screening should ultimately improve survival, reduce suffering, or enhance quality of life. Detecting more cancer alone is not enough.
A More Nuanced Narrative
The takeaway is not that early-onset cancer is irrelevant or that screening is unnecessary. Rather, it is that rising diagnoses do not automatically mean rising danger.
Cancer mortality among adults younger than 50 has declined substantially since the 1990s. At the same time, other causes of death, including accidents, overdoses, and suicide, account for far more deaths in this age group and continue to rise.
Context matters. Without it, well-intended efforts to find cancer earlier may inadvertently cause harm.
Conclusion
According to the JAMA Internal Medicine analysis, the rise in early-onset cancer appears to be less an epidemic of disease and more an epidemic of diagnosis.
While a small increase in clinically meaningful cancer exists for certain sites, most of the growth reflects heightened diagnostic scrutiny rather than a surge in deadly illness. Policymakers, clinicians, and the public should approach early detection thoughtfully, balancing potential benefits against the very real risks of overdiagnosis and overtreatment.
Source:
Patel VR, Adamson AS, Welch HG. The Rise in Early-Onset Cancer in the US Population: More Apparent Than Real. JAMA Internal Medicine. Published online September 29, 2025.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2839347
